Pfizer Inc. (NYSE:PFE) has recently launched a multi-year cost reduction initiative aimed at saving approximately $1.5 ...
Pfizer, which is going through a cost-cutting program after misreading future sales of its Covid products, said patients will have access to same-day appointments with independent healthcare ...
Pfizer Inc.’s stock rose 2.7% early Tuesday, after the company blew past earnings estimates for the second quarter, offered an update on a cost-cutting ... optimization program, EPS came to ...
"The insights gained from this combination vaccine trial are highly valuable and will play a crucial role in guiding the further development of Pfizer’s and our combination vaccine program against ...
The revision comes in response to the potential increased competition from Pfizer (NYSE:PFE)'s successful Phase 3 gene therapy trial for Hemophilia A. Metagenomi, which is developing its own ...
Under the new offering, which is meant for patients paying on their own without insurance, 2.5-milligram vials will cost $399 for one month’s supply, and 5-milligram vials will cost $549 ...
“The insights gained from this combination vaccine trial are highly valuable and will play a crucial role in guiding the further development of Pfizer’s and our combination vaccine program ...
Pfizer has said it will shed staff and cut its operating costs by around $3.5 billion, as it faces a shortfall in COVID-19 vaccine and treatment sales, with revenues now expected to be down around ...
But those days are over, and many pharma companies are looking to cut costs as they contend with a slowdown. While many companies, from Pfizer to Bristol-Myers Squibb to Bayer and Novartis ...
David Risinger’s rating is based on a careful evaluation of Pfizer’s financial outlook and strategic initiatives. He acknowledges the positive impact of the company’s cost control measures ...